Drugs aimed at a sliver of Parkinson’s patients may benefit many more than thought — and boost a biotech

Drugs aimed at a sliver of Parkinson’s patients may benefit many more than thought — and boost a biotech

Source: 
Stat
snippet: 

It’s Christmas in July for at least one small biotech and, possibly, some major pharmaceutical companies. They had assumed a class of drugs they’re developing might work in a rare, genetic form of Parkinson’s disease that accounts for 3 or 4 percent of cases.